DR-083 Technology Assessment of Next Generation Sequencing in Personalized Oncology (TANGO)
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-083 Technology Assessment of Next Generation Sequencing in Personalized Oncology (TANGO)
“Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. Since 2005, standard treatment consists of …
DR-082 Identification of gene signatures predictive for response to taxane-based treatment regimens
While localized prostate cancer can be cured, metastastatic disease is associated with high morbidity and mortality. Prostate cancer typically metastasizes …
DR-081 Gallbladder cancer, time for improvement: molecular characterization of a rare tumor to identify novel therapeutic targets.
This project concerns a feasibility study, in which tumor biopsies collected in different hospitals in the CPCT-02 trial will be …
DR-080 The tumor-stroma ratio (TSR) as predictor of response to checkpoint inhibitors in patients with gastrointestinal malignancies
“Venous thromboembolism (VTE), a venous blood clot, frequently occurs in cancer patients, and substantially affects morbidity, quality of life, …
DR-079 Technology Assessment of Next Generation Sequencing in Personalized Oncology (TANGO)
The introduction of new therapeutic options, i.e. antiangiogenic drugs and immunotherapy, has significantly changed the treatment and perspectives of patients …
DR-078 Studying the biology and clonal evolution of the cancer epigenome by integrating somatic alterations with epigenetic maps
We aim to stratify cancer types by the degree of intratumour heterogeneity demonstrated both between metastases (when the cancer spreads) …
DR-077 Identification of metastasis-driving long noncoding RNAs
The treatment of metastatic colorectal cancer (mCRC) is still based on traditional chemotherapies. mCRC is a very heterogeneous disease, and …
DR-076 Whole genome Sequencing to estimate TEmozolomide Associated Response IN Gliomas (STEARING)
Breast cancer is the most common cancer among women Worldwide. Inherited variants in breast cancer susceptibility genes or other regions …
DR-075 Measuring the evolutionary dynamics of positive and negative selection in metastatic cancers.
Numerous environmental triggers have been found to leave a footprint on the DNA of human cancers. By treating human cells …
DR-074 Modeling the pan-cancer molecular landscape and predicting drug response in metastatic cancer
Personalized medicine driven treatments in major diseases like non-small cell lung cancer (NSCLC) and melanoma offer important health benefits to …
DR-071 “Characterisation and in-depth analysis of the genome and clinical correlates of metastatic prostate cancer patients for improved patient stratification. DR-071 is an extension of DR-011”
“In this project we aim to use whole genome sequencing data to improve the way we treat patients with prostate …
DR-070 Mutational status of stage IV small intestinal neuroendocrine tumors and its effect on therapy and prognosis
“Small intestinal neuroendocrine tumors (SI-NETs) represent a heterogenous group of rare tumors. At time of diagnosis approximately 50% of patients …
In ons vak is het heel belangrijk om naast de kennis over de patiënt meer kennis te hebben van de tumor van de patiënt.